Organization (Industry)
SUPERNUS PHARMACEUTICALS, INC.
ClinicalTrials.gov lists SUPERNUS PHARMACEUTICALS, INC. as lead sponsor of 70 trials, counting the companies grouped under it. SUPERNUS PHARMACEUTICALS, INC. itself has 21 active development programs and 7 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers SUPERNUS PHARMACEUTICALS, INC. and 1 company grouped under it: 70 lead-sponsored trials (64 its own, 6 in the grouped companies) and 3 legal-entity registrations (2 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Sage Therapeutics (United States) | 6 | 1 |
Disease areas (19)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Attention Deficit Disorder with Hyperactivity | 22 |
| Epilepsy | 11 |
| Depression, Postpartum | 7 |
| Dementia | 6 |
| Epilepsies, Partial | 6 |
Showing 5 of 19 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 6 |
| 2021 | 6 |
| 2020 | 4 |
| 2019 | 4 |
| 2018 | 7 |
| 2017 | 7 |
Showing 10 of 18 years.
Prediction, not a registry value: median of 32 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 12 months across 52 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (21)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| SPN-810 | Attention Deficit Disorder with Hyperactivity | Phase 3 | 7 |
| SAGE-718 | Dementia | Phase 3 | 6 |
| SAGE-718 | Huntington Disease | Phase 3 | 4 |
| SAGE-547 90 μg/kg/h | Depression, Postpartum | Phase 3 | 2 |
| SAGE-547 60 μg/kg/h | Depression, Postpartum | Phase 3 | 1 |
Showing 5 of 21 active programs.
Approved assets (7)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Brexanolone | 8 |
| SPN-812 | 6 |
| 100mg SPN-812 | 3 |
| SPN-538 | 1 |
| SPN-810 | 8 |
Showing 5 of 7 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 55% hit target (n=31) | 26% on time (n=31) |
Journals published in (20)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of clinical psychiatry | 4 |
| CNS drugs | 3 |
| Clinical therapeutics | 2 |
| Journal of child and adolescent psychopharmacology | 2 |
| Journal of clinical psychopharmacology | 2 |
Showing 5 of 20 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 81 | 13 | 2025-10-28 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 718,952,000 | -38,550,000 | 106,235,000 |
| 2024 | 661,817,000 | 73,865,000 | 108,796,000 |
| 2023 | 607,521,000 | 1,316,000 | 91,593,000 |
| 2022 | 667,238,000 | 60,711,000 | 74,552,000 |
| 2021 | 579,775,000 | 53,424,000 | 90,467,000 |
| 2020 | 520,397,000 | 126,950,000 | 75,961,000 |
| 2019 | 392,755,000 | 113,056,000 | 69,099,000 |
| 2018 | 408,897,000 | 110,993,000 | 89,209,000 |
| 2017 | 302,238,000 | 57,284,000 | 49,577,000 |
| 2016 | 215,003,000 | 91,221,000 | 42,791,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (19)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-08-03 | Other financing | not disclosed | Sec extracted |
| 2026-08-03 | Other financing | not disclosed | Sec extracted |
| 2026-08-03 | Other financing | not disclosed | Sec extracted |
| 2026-08-01 | Debt financing | not disclosed | Sec extracted |
| 2026-05-17 | Other financing | not disclosed | Sec extracted |
Showing 5 of 19 events.
FDA untitled letters (2)
Shown in this order: most recent issue date first.
| Issue date | Letter |
|---|---|
| 2025-09-09 | 188725 |
| 2025-09-09 | 188727 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 6 |
FDA recalls (2)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Trokendi XR, topiramate extended-release capsules, 25mg, 30 Capsules, Rx only, Manufactured by: Catalent Pharma Solutions, Winchester, KY 40391 USA, Manufactured for: Supernus Pharmaceuticals, Inc., Rockville, MD 20850 USA, NDC 17772-101-30. | Class III | 2026-07-06 |
| Trokendi XR (topiramate) extended-release capsule, 50mg, 30-count blister pack, Rx only, Manufactured by: Catalent Pharma Solutions, Winchester, KY 40391, Manufactured for: Supernus Pharmaceuticals, Inc., Rockville, MD 20850, NDC 17772-102-15 | Class II | 2016-07-12 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Supernus Pharmaceuticals Inc | Rockville, US | FDA, Health Canada |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Minnesota System | Co sponsors trial with | 1 |
| Parexel | Uses vendor | 1 |
Latest dated events (187)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-03 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-08-03 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-08-03 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-08-01 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-07-06 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 187 events.
Biomarker capability evidence (170)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Primary endpoint in a Phase 3 trial |
| DEAF1 | Trial sponsor | Named in trial inclusion criteria |
| DEAF1 | Trial sponsor | Named in trial inclusion criteria |
| DEAF1 | Trial sponsor | Named in trial inclusion criteria |
| DEAF1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 170 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.